COMMUNIQUÉS West-GlobeNewswire

Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study
29/10/2018
Top line results showed larazotide having a significant effect on intestinal permeability, a mechanism thought to be key for bacterial translocation leading to NAFLD/NASH Further preclinical data in combination with [...]
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
29/10/2018
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and [...]
RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018
29/10/2018
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL- [...]
Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018
29/10/2018
CRANBURY, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to [...]
Vical Reports Third Quarter 2018 Financial and Operational Results
29/10/2018
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of 2018 was $1.5 million, or $ [...]
Transactions under Novozymes’ stock buyback program
29/10/2018
Please read the full announcement in the attached PDF Attachment 2018_61_Stock_Buybackprogram_EN
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
29/10/2018
Study confirms the good performance of tau PET-tracer 18 F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11 th Clinical Trials on [...]
Dynavax to Host Third Quarter 2018 Financial Results Conference Call
29/10/2018
BERKELEY, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30, 2018 after market close [...]
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
29/10/2018
Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's disease Study on PET [...]
Aino Health AB (publ): Aino Health and Finla in new partnered delivery
29/10/2018
2018-10-29 Aino Health's strategic partner Finla has signed its first client contract regarding Aino HealthManager in Finland. The contract encompasses 3,000 new subscribers to Aino's SaaS solution HealthManager. The [...]
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY
29/10/2018
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN CONCENTRATION AND TRANSFERRIN SATURATION IN PATIENTS UNDERGOING HAEMODIALYSIS Results from the PIVOTAL [...]
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
29/10/2018
Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development [...]
Biocartis Group NV: Shareholding Disclosure
29/10/2018
PRESS RELEASE : REGULATED INFORMATION 29 October 2018, 07:01 CET Shareholding Disclosure Mechelen, Belgium, 29 October 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics [...]
Biocartis Group NV: Disclosure of a transparency notification
29/10/2018
PRESS RELEASE : REGULATED INFORMATION 29 October 2018, 07:00 CET Disclosure of a transparency notification Mechelen, Belgium, 29 October 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
29/10/2018
Full Antagonist Mechanism of Action Demonstrated In Vivo Long-term Control of Specific Memory T Cell Mediated Autoimmunity and Chronic Inflammation NANTES, France, Oct. 29, 2018 (GLOBE NEWSWIRE) -- OSE [...]
Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer
29/10/2018
Press Release Gosselies, Belgium, 29 October 2018, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, [...]
Bone Therapeutics annonce la nomination de Linda Lebon au poste de Chief Regulatory Officer
29/10/2018
Communiqué de presse Gosselies, Belgique, le 29 octobre 2018, 7h CET - BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non [...]
Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018
27/10/2018
Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C., Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced data from two preclinical [...]
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
27/10/2018
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness [...]

Pages